Dragonfly Therapeutics, Inc
Dragonfly Therapeutics is a clinical-stage biotech company dedicated to revolutionizing disease treatment by inventing natural killer cell-based therapies. They focus on autoimmune disease, oncology, fibrosis, neuro-inflammation, neurology, and beyond, building drugs with proprietary platforms TriNKET® and CYTOKINE. Their mission is to harness the power of the immune system for vastly improved patient outcomes. The company was launched in 2016 by leading figures in disease biology and immunology, including Tyler Jacks, Bill Haney, and David Raulet, with a scientific advisory board comprising Nobel laureates and world-class experts in immunology and cancer biology. Their therapies are designed to be potent as single agents and in combination with existing treatments, aiming to provide breakthrough therapies for patients.
Industries
Nr. of Employees
medium (51-250)
Dragonfly Therapeutics, Inc
Waltham, Massachusetts, United States, North America
Products
HER2‑targeting tri‑specific NK/T cell engager (clinical‑stage)
A multi‑specific engager designed to redirect NK cells and CD8+ T cells to HER2‑expressing tumors; evaluated in early‑phase clinical studies as monotherapy and in combination with antibody–drug conjugates and checkpoint inhibitors.
EGFR‑targeting tri‑specific NK cell engager (clinical‑stage)
A multi‑specific engager directing NK cell activity to EGFR‑expressing tumors; developed for solid tumor indications and evaluated in combination with checkpoint inhibitors.
Engineered IL‑2‑based cytokine agonist (clinical‑stage)
An engineered IL‑2 cytokine with modified receptor activity designed to increase therapeutic index and demonstrate efficacy alone and in combination with PD‑1 pathway blockade in preclinical and early clinical studies.
IL‑12 Fc‑fusion cytokine with extended half‑life (clinical‑stage / licensed)
An Fc‑fusion cytokine engineered to prolong circulation and modulate the tumor microenvironment to increase inflammatory anti‑tumor responses; subject to partner licensing arrangements.
Portfolio of partner‑licensed multi‑specific engager candidates
Multiple multi‑specific engager candidates that have been optioned or licensed to external pharmaceutical partners for further development across oncology and related indications.
HER2‑targeting tri‑specific NK/T cell engager (clinical‑stage)
A multi‑specific engager designed to redirect NK cells and CD8+ T cells to HER2‑expressing tumors; evaluated in early‑phase clinical studies as monotherapy and in combination with antibody–drug conjugates and checkpoint inhibitors.
EGFR‑targeting tri‑specific NK cell engager (clinical‑stage)
A multi‑specific engager directing NK cell activity to EGFR‑expressing tumors; developed for solid tumor indications and evaluated in combination with checkpoint inhibitors.
Engineered IL‑2‑based cytokine agonist (clinical‑stage)
An engineered IL‑2 cytokine with modified receptor activity designed to increase therapeutic index and demonstrate efficacy alone and in combination with PD‑1 pathway blockade in preclinical and early clinical studies.
IL‑12 Fc‑fusion cytokine with extended half‑life (clinical‑stage / licensed)
An Fc‑fusion cytokine engineered to prolong circulation and modulate the tumor microenvironment to increase inflammatory anti‑tumor responses; subject to partner licensing arrangements.
Portfolio of partner‑licensed multi‑specific engager candidates
Multiple multi‑specific engager candidates that have been optioned or licensed to external pharmaceutical partners for further development across oncology and related indications.
Services
Collaborative research and partnered development
Co‑development agreements and research collaborations to discover, preclinically characterize, and advance therapeutic candidates into clinical development with external partners.
Licensing and out‑licensing of therapeutic candidates
Negotiation and execution of licensing transactions, option agreements, and milestone/royalty arrangements for clinical‑stage and preclinical candidates to enable partner‑led development.
Collaborative research and partnered development
Co‑development agreements and research collaborations to discover, preclinically characterize, and advance therapeutic candidates into clinical development with external partners.
Licensing and out‑licensing of therapeutic candidates
Negotiation and execution of licensing transactions, option agreements, and milestone/royalty arrangements for clinical‑stage and preclinical candidates to enable partner‑led development.
Expertise Areas
- NK cell engager immunotherapy
- Engineered cytokines and Fc‑fusion biologics
- Protein and ligand engineering with structural guidance
- Immuno‑oncology and combination therapy development
Key Technologies
- Multi‑specific immune engagers (tri‑/multi‑specific formats)
- Engineered cytokines and Fc‑fusion proteins
- Protein engineering and ligand design
- Structural biology of receptor–ligand interactions